# Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema

> **NCT04387604** · — · COMPLETED · sponsor: **Centro Hospitalar do Porto** · enrollment: 50 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]

## Key facts

- **NCT ID:** NCT04387604
- **Lead sponsor:** Centro Hospitalar do Porto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2018-02-01
- **Final completion:** 2019-03-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04387604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04387604, "Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04387604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*